Sec Form 4 Filing - DOW GEOFFREY S @ 60 DEGREES PHARMACEUTICALS, INC. - 2023-11-21

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person DOW GEOFFREY S 2. Issuer Name and Ticker or Trading Symbol 60 DEGREES PHARMACEUTICALS, INC. [ SXTP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O 60 DEGREES PHARMACEUTICALS, INC., 1025 CONNECTICUT AVENUE NW SUITE 1000 3. Date of Earliest Transaction (MM/DD/YY) 11/21/2023 (Street) WASHINGTON, DC20036 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock ( 1 ) 04/12/2024 M 68,000 ( 1 ) A $ 0.2668 745,625 ( 1 ) D ( 1 ) Common Stock ( 2 ) 05/16/2024 M 17,000 ( 1 ) A $ 0.223 762,625 ( 2 ) D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 3 ) $ 0 11/21/2023 A 85,000 ( 3 ) ( 3 ) ( 3 ) Common Stock 85,000 ( 3 ) $ 0 85,000 D Restricted Stock Units ( 3 ) ( 4 ) $ 0 04/12/2024 M 68,000 ( 4 ) ( 4 ) ( 4 ) Common Stock 68,000 ( 4 ) $ 0 17,000 D Restricted Stock Units ( 3 ) ( 5 ) $ 0 05/16/2024 M 17,000 ( 5 ) ( 5 ) ( 5 ) Common Stock 17,000 ( 5 ) $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other DOW GEOFFREY S C/O 60 DEGREES PHARMACEUTICALS, INC. 1025 CONNECTICUT AVENUE NW SUITE 1000 WASHINGTON, DC20036 X President and CEO Signatures /s/ Geoffrey Dow 05/21/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Geoffrey Dow was granted a total of 85,000 restricted stock units ("RSUs") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the "4/24 Shares"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the "Dow Trust"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust. ( 2 )17,000 shares underlying the RSUs were settled on May 16, 2024 (the "5/24 Shares"). Geoffrey Dow owned 78,482 shares of common stock and through the Dow Trust owned 667,143 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Geoffrey Dow owned a total of 762,625 shares of common stock, consisting of (i) 95,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust. ( 3 )Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. ( 4 )68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs. ( 5 )17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.